Phibro Animal Health Corp (PAHC)

$17.07

+0.31

(+1.85%)▲

Market is closed - opens 7 PM, 06 May 2024

Insights on Phibro Animal Health Corp

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 231.3M → 249.94M (in $), with an average increase of 7.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -8.0M → 1.27M (in $), with an average increase of 727.9% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 41.8% return, outperforming this stock by 34.4%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 49.3% return, outperforming this stock by 85.7%

Performance

  • $16.58
    $17.20
    $17.07
    downward going graph

    2.87%

    Downside

    Day's Volatility :3.6%

    Upside

    0.76%

    downward going graph
  • $9.02
    $17.10
    $17.07
    downward going graph

    47.16%

    Downside

    52 Weeks Volatility :47.25%

    Upside

    0.18%

    downward going graph

Returns

PeriodPhibro Animal Health CorpSector (Health Care)Index (Russel 2000)
3 Months
56.34%
-1.1%
0.0%
6 Months
35.82%
10.3%
0.0%
1 Year
7.44%
5.3%
1.7%
3 Years
-36.37%
14.5%
-22.3%

Highlights

Market Capitalization
508.7M
Book Value
$6.69
Dividend Share
0.48
Dividend Yield
3.82%
Earnings Per Share (EPS)
0.37
PE Ratio
33.95
PEG Ratio
1.66
Wall Street Target Price
10.75
Profit Margin
1.51%
Operating Margin TTM
6.41%
Return On Assets TTM
3.72%
Return On Equity TTM
5.49%
Revenue TTM
982.0M
Revenue Per Share TTM
24.25
Quarterly Revenue Growth YOY
2.1999999999999997%
Gross Profit TTM
298.2M
EBITDA
91.0M
Diluted Eps TTM
0.37
Quarterly Earnings Growth YOY
-0.83
EPS Estimate Current Year
1.1
EPS Estimate Next Year
1.23
EPS Estimate Current Quarter
0.28
EPS Estimate Next Quarter
0.3

Analyst Recommendation

Sell
    11%Buy
    33%Hold
    55%Sell
Based on 9 Wall street analysts offering stock ratings for Phibro Animal Health Corp(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
3
3
3
Sell
5
5
5

Analyst Forecast

What analysts predicted

Downside of 37.02%

Current $17.07
Target $10.75

Company Financials

FY18Y/Y Change
Revenue
820.0M
↑ 7.29%
Net Income
64.9M
↑ 0.46%
Net Profit Margin
7.91%
↓ 0.54%
FY19Y/Y Change
Revenue
828.0M
↑ 0.98%
Net Income
54.7M
↓ 15.72%
Net Profit Margin
6.61%
↓ 1.3%
FY20Y/Y Change
Revenue
800.4M
↓ 3.33%
Net Income
33.6M
↓ 38.66%
Net Profit Margin
4.19%
↓ 2.42%
FY21Y/Y Change
Revenue
833.4M
↑ 4.12%
Net Income
54.4M
↑ 62.09%
Net Profit Margin
6.53%
↑ 2.34%
FY22Y/Y Change
Revenue
942.3M
↑ 13.07%
Net Income
49.2M
↓ 9.58%
Net Profit Margin
5.22%
↓ 1.31%
FY23Y/Y Change
Revenue
977.9M
↑ 3.78%
Net Income
32.6M
↓ 33.69%
Net Profit Margin
3.33%
↓ 1.89%
Q3 FY22Q/Q Change
Revenue
232.5M
↓ 8.92%
Net Income
3.9M
↓ 48.59%
Net Profit Margin
1.66%
↓ 1.28%
Q4 FY22Q/Q Change
Revenue
244.6M
↑ 5.21%
Net Income
7.2M
↑ 86.98%
Net Profit Margin
2.95%
↑ 1.29%
Q1 FY23Q/Q Change
Revenue
245.7M
↑ 0.43%
Net Income
10.0M
↑ 39.28%
Net Profit Margin
4.09%
↑ 1.14%
Q2 FY23Q/Q Change
Revenue
255.0M
↑ 3.81%
Net Income
11.5M
↑ 14.5%
Net Profit Margin
4.51%
↑ 0.42%
Q3 FY23Q/Q Change
Revenue
231.3M
↓ 9.31%
Net Income
-8.0M
↓ 169.58%
Net Profit Margin
-3.46%
↓ 7.97%
Q4 FY23Q/Q Change
Revenue
249.9M
↑ 8.06%
Net Income
1.3M
↓ 115.92%
Net Profit Margin
0.51%
↑ 3.97%
FY18Y/Y Change
Total Assets
671.7M
↑ 7.74%
Total Liabilities
486.7M
↑ 3.07%
FY19Y/Y Change
Total Assets
726.7M
↑ 8.19%
Total Liabilities
510.7M
↑ 4.92%
FY20Y/Y Change
Total Assets
784.1M
↑ 7.9%
Total Liabilities
595.9M
↑ 16.69%
FY21Y/Y Change
Total Assets
841.3M
↑ 7.3%
Total Liabilities
602.8M
↑ 1.16%
FY22Y/Y Change
Total Assets
931.7M
↑ 10.74%
Total Liabilities
669.3M
↑ 11.03%
FY23Y/Y Change
Total Assets
971.4M
↑ 4.26%
Total Liabilities
688.9M
↑ 2.93%
Q3 FY22Q/Q Change
Total Assets
948.4M
↑ 1.79%
Total Liabilities
685.6M
↑ 2.45%
Q4 FY22Q/Q Change
Total Assets
961.8M
↑ 1.42%
Total Liabilities
693.5M
↑ 1.14%
Q1 FY23Q/Q Change
Total Assets
965.4M
↑ 0.37%
Total Liabilities
693.1M
↓ 0.05%
Q2 FY23Q/Q Change
Total Assets
971.4M
↑ 0.62%
Total Liabilities
688.9M
↓ 0.61%
Q3 FY23Q/Q Change
Total Assets
964.5M
↓ 0.71%
Total Liabilities
691.5M
↑ 0.37%
Q4 FY23Q/Q Change
Total Assets
972.7M
↑ 0.85%
Total Liabilities
701.9M
↑ 1.51%
FY18Y/Y Change
Operating Cash Flow
70.0M
↓ 28.85%
Investing Cash Flow
-84.6M
↑ 285.62%
Financing Cash Flow
-11.8M
↓ 78.09%
FY19Y/Y Change
Operating Cash Flow
47.2M
↓ 32.62%
Investing Cash Flow
-14.1M
↓ 83.3%
Financing Cash Flow
-4.1M
↓ 65.12%
FY20Y/Y Change
Operating Cash Flow
59.3M
↑ 25.82%
Investing Cash Flow
-120.4M
↑ 751.84%
Financing Cash Flow
40.9M
↓ 1096.74%
FY21Y/Y Change
Operating Cash Flow
48.3M
↓ 18.61%
Investing Cash Flow
-18.6M
↓ 84.57%
Financing Cash Flow
-17.0M
↓ 141.52%
FY22Y/Y Change
Operating Cash Flow
31.6M
↓ 34.48%
Investing Cash Flow
-22.6M
↑ 21.54%
Financing Cash Flow
16.3M
↓ 196.16%
FY23Y/Y Change
Operating Cash Flow
13.3M
↓ 57.94%
Investing Cash Flow
-74.0M
↑ 227.77%
Financing Cash Flow
27.0M
↑ 65.13%
Q3 FY22Q/Q Change
Operating Cash Flow
-10.7M
↓ 779.67%
Investing Cash Flow
-16.1M
↑ 69.28%
Financing Cash Flow
29.3M
↑ 136.65%
Q4 FY22Q/Q Change
Operating Cash Flow
-2.5M
↓ 76.73%
Investing Cash Flow
-9.8M
↓ 39.25%
Financing Cash Flow
3.7M
↓ 87.33%
Q1 FY23Q/Q Change
Operating Cash Flow
6.3M
↓ 351.47%
Investing Cash Flow
-37.8M
↑ 285.09%
Financing Cash Flow
284.0K
↓ 92.36%
Q2 FY23Q/Q Change
Operating Cash Flow
20.2M
↑ 223.34%
Investing Cash Flow
-10.3M
↓ 72.78%
Financing Cash Flow
-6.3M
↓ 2329.58%

Technicals Summary

Sell

Neutral

Buy

Phibro Animal Health Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Phibro Animal Health Corp
Phibro Animal Health Corp
29.62%
35.82%
7.44%
-36.37%
-53.56%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
1.63%
24.36%
41.79%
49.34%
77.07%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
0.97%
3.1%
-4.04%
12.28%
12.28%
Zoetis Inc.
Zoetis Inc.
2.61%
3.08%
-5.91%
-4.57%
61.19%
Viatris Inc.
Viatris Inc.
-3.49%
25.13%
26.91%
-14.07%
-29.01%
Catalent, Inc.
Catalent, Inc.
-0.6%
59.74%
15.36%
-49.6%
23.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Phibro Animal Health Corp
Phibro Animal Health Corp
33.95
33.95
1.66
1.1
0.05
0.04
0.04
6.69
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
56.26
56.26
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
30.0
30.0
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.76
29.76
2.58
5.79
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
229.4
229.4
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Phibro Animal Health Corp
Phibro Animal Health Corp
Sell
$508.7M
-53.56%
33.95
1.51%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.1B
77.07%
56.26
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.4B
12.28%
30.0
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.9B
61.19%
29.76
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.6B
-29.01%
229.4
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
23.04%
211.02
-31.77%

Institutional Holdings

  • BlackRock Inc

    9.06%

  • Brandes Investment Partners & Co

    5.26%

  • Pzena Investment Management, LLC

    4.91%

  • Vanguard Group Inc

    4.44%

  • State Street Corporation

    2.34%

  • Dimensional Fund Advisors, Inc.

    1.92%

Corporate Announcements

  • Phibro Animal Health Corp Dividends March,2024

    In the quarter ending March,2024. Phibro Animal Health Corp has declared dividend of $0.12

    Read More

Company Information

phibro animal health corporation is a leading global diversified animal health and mineral nutrition company. we are dedicated to helping meet the growing demand for animal protein. we concentrate exclusively on animals for food production and are one of the few global companies offering a comprehensive range of animal health and mineral nutrition products. for over 40 years we have been committed to providing livestock producers with value-based products and solutions to help them maintain and enhance the health of their animals. we develop, manufacture and market a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. our products help prevent, control and treat diseases, enhance nutrition to help improve health and contribute to balanced mineral nutrition. phibro animal health corporation reported net sales of $764 million for the fiscal year ended june 30, 2017. our more than 1,400 employees are proud to manufacture and market our

Organization
Phibro Animal Health Corp
Employees
1920
CEO
Mr. Jack Clifford Bendheim
Industry
Health Technology

Discover More

FAQs